Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Neurology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Alzheimer's Disease Clinical Trials

A listing of Alzheimer's Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (11) clinical trials

Safety Tolerability PK and PD of Posiphen in Subjects With Early Alzheimer's Disease

Posiphen, which was discovered by the US National Institute on Aging (NIA) is a small, orally active, experimental drug that specifically inhibits the synthesis of amyloid precursor protein (APP), Tau and -Synuclein. It is distinct from other Alzheimer's disease drugs currently in development, because it inhibits the formation of several ...

Phase

Study of LM11A-31-BHS in Mild-moderate AD Patients

The goal of this AD Pilot is to conduct a prospective, double-blind, multicenter, phase IIa exploratory safety, feasibility and proof-of-concept trial in mild to moderate Alzheimer's disease patients with the orally bioavailable p75 neurotrophin receptor ligand LM11A-31-BHS dosed twice daily for 26 weeks. Successful completion of this trial will provide ...

Phase

Safety Tolerability Pharmacokinetics and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild Alzheimer's Disease

Allocation: RandomizedEndpoint Classification: Safety Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment

Phase

Safety and Exploratory Efficacy Study of NEUROSTEM Versus Placebo in Patients With Alzheimer's Disease

The study is divided into the 2 stages: dose-escalation in stage 1 and randomized and multiple-dose cohort parallel design in stage 2.The target population for enrollment in this study is patients with mild to moderate Alzheimer's disease.

Phase

Blood Brain Barrier Opening in Alzheimer' Disease

Background Alzheimer's disease is the most prevalent neurodegenerative disease totalizing 33 million patients worldwide. If nothing is done to decrease the incidence of 1.8 Million patient/year, the prevalence will double in the next 20 years. Physiopathologically, the amyloid cascade remains the predominant hypothesis. It states that an imbalance between the ...

Phase

A Study to Evaluate the Safety and Efficacy of AstroStem in Treatment of Alzheimer's Disease

This is a randomized, double-blind, placebo-controlled, parallel-group comparison study in subjects with Alzheimer's Disease. Following first screening period, subjects will be randomly assigned into one of the following arms: AstroStem and placebo control in a 1:1 ratio. AstroStem or placebo control will be administered via I.V. at Week 0. This ...

Phase

S-Equol in Alzheimer's Disease 2 Trial

By doing this study researchers hope to learn if S-equol, a compound that acts like estrogen in the body, causes an increase in mitochondrial activity. Researchers also hope to determine the safety and tolerability of a therapeutic dose of S-equol and whether or not it influences cognition.

Phase

Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells in Patients With Alzheimer's Disease

Autologous Adipose-derived Stromal Vascular Fraction (AD-SVF) will be infused intra-venous and Intra nasal. The therapy is composed of cells derived from a patients' own adipose tissue that are isolated within approximately 1 hour and immediately delivered back to the patient.

Phase

Chronic Electrical Stimulation of Hypothalamus/Fornix in Alzheimer's Disease

Alzheimer's Disease (AD) is the most common cause of dementia for which no treatment has shown consistent efficacy to stop or slow down the disease. Recent report of enhancement of memory abilities by bilateral chronic deep brain stimulation (DBS) of the fornix in the hypothalamus suggests that neuromodulation of circuits ...

Phase

Donepezil and Brain Activity Patterns in Those at Risk For Alzheimer's Disease

HYPOTHESIS 1. Cognitively intact individuals with normal brain morphology at genetic risk for developing Alzheimer's' Disease (AD) show alterations in brain activation patterns during tasks that require memory compared to similar individuals with lower risk for developing AD. 2. Donepezil, a cholinesterase inhibitor, can normalize such brain activation patterns in ...

Phase